Vascular Biology |
From the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease (D.W., S.O., Y.-F.C., W.F.) and the Division of Clinical Immunology and Rheumatology (M.A.M., G.A.S., A.J.S.), Department of Medicine, the University of Alabama at Birmingham.
Correspondence to Alexander J. Szalai, PhD, the University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, THT 437B, 1530 3rd Avenue South, Birmingham, Alabama 35294-0006. E-mail Alex.Szalai{at}ccc.uab.edu
Objective Previously we established that the vascular injury response was attenuated in ovariectomized wild-type rodents treated with 17ß-estradiol (E2). We also showed that the response to acute vascular injury in transgenic mice expressing human C-reactive protein (CRPtg) is exaggerated compared with their nontransgenic (NTG) counterparts. Herein we tested the hypothesis that E2 modulates vascular injury in the CRPtg mouse.
Methods and Results Intact (INT) or ovariectomized (OVX) CRPtg and NTG, treated with E2 or vehicle, had their right common carotid artery ligated. Resultant neointima formation was exaggerated in CRPtg compared with NTG, whether INT or OVX, but was prevented in both genotypes by E2. Expression of human CRP protein (immunohistochemical analysis) and mRNA (laser microdissection followed by real-time quantitative RT-PCR) was detected in the neointima of OVX CRPtg and was greatly diminished by E2 treatment. CRP was not detected in uninjured arteries or in the media of injured arteries, and blood CRP level was consistently low.
Conclusions The exaggerated response to vascular injury in CRPtg is associated with increased neointimal expression of human CRP. E2 reduces both neointima formation and neointimal expression of human CRP, suggesting that E2 is vasoprotective.
We tested whether estrogen could modulate the exaggerated vascular response to injury seen in C-reactive protein (CRP) transgenic mice. Estrogen treatment reduced carotid artery ligationinduced expression of CRP (protein and mRNA) in the neointima, and lessened CRP-mediated exacerbation of injury. These data suggest that estrogen is vasoprotective.
Key Words: C-reactive protein estrogen hormone replacement therapy cardiovascular disease inflammation
This article has been cited by other articles:
![]() |
D. Xing, S. Nozell, Y.-F. Chen, F. Hage, and S. Oparil Estrogen and Mechanisms of Vascular Protection Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 289 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wu, M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn, and W. P. Fay C-Reactive Protein Enhances Tissue Factor Expression by Vascular Smooth Muscle Cells: Mechanisms and In Vivo Significance Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 698 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Hage and A. J. Szalai C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1115 - 1122. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |